Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.0
3.4
Journals
Life
Special Issues
Research and Management of Endocrine Tumors
share announcement

Research and Management of Endocrine Tumors

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: 31 January 2027 | Viewed by 964

Special Issue Editor

Dr. Ifigenia Kostoglou-Athanassiou

E-Mail Website
Guest Editor
Department of Endocrinology, Asklepeion General Hospital, Athens, Greece
Interests: breast cancer; neuroendocrinology; melatonin; thyroid cancer; vitamin D; autoimmune diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Endocrine tumors continue to be a problem for many patients all over the world.  In particular, thyroid cancer has has a significant increase in incidence and prevalence in recent years. Thyroid cancer is the most common endocrine cancer. In many cases, it is a benign form of malignancy. However, there are many cases of thyroid cancer that present with metastatic progressive disease. In these cases, novel therapeutic agents are applied, called multiple kinase inhibitors. Since their discovery, these therapeutic agents have offered new hope for patients with progressive metastatic disease. As the pathophysiology and prognosis of thyroid cancer becomes better understood, the indications for treatment with radioiodine will change. Treatment with radioiodine, its indications, and procedural changes will be upgraded as our understanding of thyroid cancer biology and pathophysiology improves. Adrenal cancer is also a medical problem that poses diagnostic and therapeutic challenges for physicians and biologists alike. With applying diagnostic methods like computer tomography and magnetic resonance imaging, the discovery of adrenal masses becomes increasingly easy. However, most of these endocrine neoplasms are benign. The differential diagnosis of a possible adrenal cancer as well as its treatment pose a diagnostic and therapeutic problem with major interest.

We look forward to receiving your contributions.

Dr. Ifigenia Kostoglou-Athanassiou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • thyroid cancer
  • papillary thyroid cancer
  • anaplastic thyroid cancer
  • radioiodine
  • multiple kinase and angiogenetic factor inhibitors
  • adrenal cancer
  • pituitary adenomas

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

11 pages, 398 KB  
Protocol
Treatment with Kinase Inhibitors Plus Myo-Inositol as Re-Differentiating Agents in Iodine-Refractory Thyroid Cancers
by Carlotta Giani, Michele Russo, Paola Lapi, Maria Antonietta Profilo, Raffaella Forleo, Barbara Mazzi, Arianna Ghirri, Lisa Caresia, Alfredo Campennì, Cosimo Durante, Andrea Corsello, Riccardo Morganti, Vittorio Unfer, Rosa Maria Paragliola and Daniele Barbaro
Life 2026, 16(3), 391; https://doi.org/10.3390/life16030391 - 28 Feb 2026
Viewed by 678
Abstract
Background and aim: Recent preclinical studies have confirmed that inhibiting the MAP kinase pathway can induce the re-differentiation of radioiodine (RAI)-refractory (RAIR) follicular cell thyroid cancers (TCs). The aim of this trial is to investigate whether the combination of kinase inhibitors (KIs) with [...] Read more.
Background and aim: Recent preclinical studies have confirmed that inhibiting the MAP kinase pathway can induce the re-differentiation of radioiodine (RAI)-refractory (RAIR) follicular cell thyroid cancers (TCs). The aim of this trial is to investigate whether the combination of kinase inhibitors (KIs) with myo-inositol (MI) can induce or potentiate the re-uptake of RAI in cancer cells. Overview and methods: This is an open label, non-pharmacological, multicenter, randomized pilot study. Patients will be divided into two groups: (1) a control group in which patients are treated with KIs (subgroup a: trametinib plus dabrafenib; subgroup b: lenvatinib); (2) a group in which patients (divided into the two subgroups) are treated with the same KIs in addition to MI. After 30 days of MI treatment, all patients, treated with levothyroxine (L-T4) at a semi-suppressive dosage as per clinical practice, will be stimulated with recombinant human TSH (rhTSH) (days 31 and 32). On day 35, the patients will be subjected to whole-body scintigraphy, with hybrid imaging where possible (SPECT/CT), after the administration of diagnostic activity (185–222 MBq of 123-I in accordance with the SNMMI/EANM guidelines. Blood samples will be collected before starting MI therapy (day 0); after 30 days of MI therapy; and then on days 31, 32, 33, 34, and 35 after MI therapy. Quality of life (QoL) will be assessed at the beginning of the MI treatment and at the end of its administration. The primary endpoint is the restoration of 123-I uptake in RAIR-TC patients already on KI therapy alone and on KI therapy plus MI. The restoration of 123-I uptake in target lesions will be evaluated. Conclusions: MI may have a synergistic effect at the cellular level, and the possible increase in the re-differentiation of RAIR-TC in patients treated with KIs plus MI may have great clinical relevance. The re-uptake of RAI will be evaluated as the primary endpoint, and Tg values and QoL will be evaluated as the secondary endpoints. The main limitation of this study is that we do not investigate any clinical effects. We will have to postpone the clinical analysis to a later date after the administration of RAI for therapeutic purposes. Full article
(This article belongs to the Special Issue Research and Management of Endocrine Tumors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop